First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer

Abstract

In an interim analysis of results among patients with previously untreated advanced <i>ALK</i>-positive NSCLC, those who received lorlatinib had significantly longer progression-free survival and a higher frequency of intracranial response than those who received crizotinib. The incidence of grade 3 or 4 adverse events was higher with lorlatinib than with crizotinib because of the frequent occurrence of altered lipid levels. (Funded by Pfizer; CROWN ClinicalTrials.gov number, NCT03052608.).